| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
GP-RCC, which has been identified in the process of searching the glycoprotein carrying sialyl T antigen, decreased in the patients with clear cell renal cell carcinoma (RCC). Serum level of GP-RCC was significantly lower in 63 patients with clear cell RCC than in 53 having benign urologic diseases without RCC (p=0.0004). Increase of serum GP-RCC level was confirmed after radical nephrectomy for clear cell RCC in five out of six patients. Molecular size (45kDa) of serum GP-RCC was larger than that (38kDa) extracted from RCC cell lines. Molecular size was decreased by glycosidase treatment of serum GP-RCC, suggesting serum GP-RCC is heavily glycolsylated compared to GP-RCC existing in RCC cell lines. From the results, it was indicated that a decrease of GP-RCC was a new marker for clear cell RCC.
|
